ACE and cardiovascular disorder: For example, increased utilization of angiotensin-converting-enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and HMG-CoA reductase inhibitors (commonly referred to as statins) for cardiovascular disease (CVD) management will likely lead to increased costs to patients.